Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial
Open Access
- 29 December 2016
- journal article
- Published by Taylor & Francis in Arab Journal of Urology
- Vol. 15 (1) , 53-59
Abstract
Objective: To assess the additive effect of sildenafil citrate to tamsulosin in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH) in men with or without erectile dysfunction (ED). Patients and methods In all, 150 men with untreated LUTS/BPH with or without ED were randomised to receive sildenafil 25 mg once daily (OD) or placebo OD (night time) combined with tamsulosin 0.4 mg OD (day time) for 6 months. Changes from pre-treatment scores in International Prostate Symptom Score (IPSS), IPSS-quality of life (QoL) score, maximum urinary flow rate (Qmax), and the five-item version of the International Index of Erectile Function questionnaire (IIEF-5) were assessed at 3 and 6 months. Safety profiles were assessed by physical examination and monitoring clinical adverse events. Results: Group A comprised of men who received tamsulosin and sildenafil (75 men), whilst those in Group B received tamsulosin and placebo (75). The IPSS was significantly improved in Group A compared to Group B, at −29.3% vs −13.7% (P = 0.039) at 3 months and −37% vs −19.6% (P = 0.043) at 6 months after treatment. Qmax significantly improved in both groups compared with before treatment (P < 0.001). The IIEF-5 scores improved more in Group A than in Group B, at 58.7% vs 11.7% at 3 months and 62.4% vs 12.4% at 6 months after treatment (both P < 0.001). Conclusion: Sildenafil citrate combined with tamsulosin improved LUTS, erectile function, and patient QoL more than tamsulosin monotherapy with the merit of a comparable safety profile in patients with LUTS/BPH.Keywords
This publication has 23 references indexed in Scilit:
- A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with α-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic HyperplasiaEuropean Urology, 2012
- Phosphodiesterase Type 5 Inhibitors in the Management of Non-neurogenic Male Lower Urinary Tract Symptoms: Critical Analysis of Current EvidenceEuropean Urology, 2011
- An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasiaAsian Journal of Andrology, 2011
- Acute Vardenafil Administration Improves Bladder Oxygenation in Spontaneously Hypertensive RatsThe Journal of Sexual Medicine, 2010
- Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.2007
- Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiologyBJU International, 2006
- Lower Urinary Tract Symptoms and Male Sexual Dysfunction: The Multinational Survey of the Aging Male (MSAM-7)European Urology, 2003
- Health-related quality of life associated with lower urinary tract symptoms in four countriesUrology, 1998
- Natural History of Prostatism: Risk Factors for Acute Urinary RetentionJournal of Urology, 1997
- ‘Prostate‐related symptoms’ in Canadian men 50 years of age or older: prevalence and relationships among symptomsBritish Journal of Urology, 1994